ANIP · Ani Pharmaceuticals Inc
$77.61
-0.93 (-1.18%)
At close · Jul 24
Market Cap
$1.77B
Shares
22.75M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$100,000,000
as of 2026-05-08
| Program Announced | Authorized | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2026-05-08 | $100,000,000 | — | — | 2029-05-01 | 8-K , filed 2026-05-08 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2026-03-31 YTD | $19,755,000 | 10-Q, filed 2026-05-08 |
| 2025-12-31 | $12,209,000 | 10-K, filed 2026-02-27 |
| 2024-12-31 | $10,959,000 | 10-K, filed 2026-02-27 |
| 2023-12-31 | $4,987,000 | 10-K, filed 2026-02-27 |
| 2022-12-31 | $1,959,000 | 10-K, filed 2025-02-28 |
| 2021-12-31 | $890,000 | 10-K, filed 2024-02-29 |
| 2020-12-31 | $1,523,000 | 10-K, filed 2023-03-09 |
| 2019-12-31 | $1,031,000 | 10-K, filed 2022-03-15 |
| 2018-12-31 | $0 | 10-K, filed 2019-02-27 |
| 2017-12-31 | $0 | 10-K, filed 2019-02-27 |
| 2016-12-31 | $2,500,000 | 10-K, filed 2019-02-27 |
| 2015-12-31 | $0 | 10-K, filed 2018-02-27 |
| 2014-12-31 | $0 | 10-K, filed 2017-03-02 |
| 2013-12-31 | $433,000 | 10-K, filed 2016-02-23 |
| 2012-12-31 | $0 | 10-K, filed 2014-02-28 |
Key facts
CIK
1023024
CUSIP
00182C103
13F (30d)
43 filings
40 filers
Visit website
Investor relations